{
  "context": {
    "rules": [
      "Rule1: Provided that the organization received grant1, then if it is not the case that (if the disease is targeted then the compound is not patented) implies the compound does not face a regulatory hurdle, then the compound achieves market launch.",
      "Rule2: Either the organization received grant1 or the organization received grant2.",
      "Rule3: Under the condition that the organization received grant2, the organization formed a partnership with the university.",
      "Rule4: In case the organization formed a partnership with the university, then if it is not the case that (if the disease is targeted then the compound is not patented) implies the compound does not face a regulatory hurdle, the compound achieves market launch.",
      "Rule5: Either public concern arises about the compound, or if it is not the case that an adverse event reported for the compound implies the clinical trial of the compound is halted, then the agency does not launch an investigation.",
      "Rule6: The compound is a drug candidate or the compound is an experimental therapy.",
      "Rule7: If the compound is an experimental therapy, then the compound is a game changer.",
      "Rule8: Under the condition that the compound is a therapeutic agent, the compound is a game changer.",
      "Rule9: Either the compound causes a side effect, or if the compound is not a game changer then the compound is approved.",
      "Rule10: Either the organization’s research focus is the compound or the organization’s development priority is the compound.",
      "Rule11: Should the organization’s development priority be the compound, then if the compound is a drug candidate, the compound is a therapeutic agent.",
      "Rule12: Under the condition that a patent was filed for the compound, a publication was released for the compound.",
      "Rule13: Either the organization performed a market analysis or the organization produced a competitor report.",
      "Rule14: In case the organization produced a competitor report, then if it is not the case that the compound not being a game changer implies a competing drug exists for the disease, then there is no market competition for the compound.",
      "Rule15: Provided that the compound is in a clinical trial, then the compound shows efficacy.",
      "Rule16: Whenever the organization is a research leader, then if it is not the case that the organization performing a market analysis implies (if it is not the case that the compound not being a game changer implies a competing drug exists for the disease, then there is no market competition for the compound), then the organization adjusts its strategy.",
      "Rule17: Should there be a legal challenge against the compound, then there is no intellectual property dispute over the compound.",
      "Rule18: Provided that the lab verified data for the compound, then if a journal submission was made for the compound, peer review is completed for the compound.",
      "Rule19: Either the lab verified data for the compound or the lab replicated results for the compound.",
      "Rule20: Should the lab replicate results for the compound, then if a journal submission was made for the compound, peer review is completed for the compound.",
      "Rule21: Whenever the compound shows efficacy, the compound does not cause a side effect.",
      "Rule22: If the compound has high potential, then in case the organization’s research focus is the compound, it follows that if the compound is a drug candidate, the compound is a therapeutic agent.",
      "Rule23: Provided that the compound has a novel mechanism, then the compound has high potential.",
      "Rule24: Either the compound has a manufacturing problem or the compound does not have a safety issue.",
      "Rule25: Under the condition that the compound was developed by the organization, the compound is patented.",
      "Rule26: Should the compound be developed by the organization, then the disease is targeted.",
      "Rule27: Either the compound was developed by the organization or the compound is a game changer.",
      "Rule28: In case it is not the case that an adverse event reported for the compound implies the clinical trial of the compound is halted, then the agency launches an investigation.",
      "Rule29: If it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent)), then a patent is filed for the compound.",
      "Rule30: Whenever it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent)), a journal submission is made for the compound.",
      "Rule31: Provided that it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent)), then peer review is not completed for the compound.",
      "Rule32: In case it is not the case that a breakthrough discovery made for the compound implies the compound has a novel mechanism, then the compound has a safety issue.",
      "Rule33: If it is not the case that the organization performing a market analysis implies (if it is not the case that the compound not being a game changer implies a competing drug exists for the disease, then there is no market competition for the compound), then the organization does not adjust its strategy.",
      "Rule34: Under the condition that it is not the case that the organization being part of a research consortium implies (if it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent)), then a publication is released for the compound), the collaboration of the organization is suspended.",
      "Rule35: Provided that it is not the case that the disease being targeted implies the compound is not patented, then the compound faces a regulatory hurdle.",
      "Rule36: Should it not be the case that (if it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent))) implies a publication is released for the compound, then there is an intellectual property dispute over the compound.",
      "Rule37: Under the condition that it is not the case that (if it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent))) implies a publication is released for the compound, there is a legal challenge against the compound.",
      "Rule38: Provided that it is not the case that (if it is not the case that the organization being part of a research consortium implies (if it is not the case that a breakthrough discovery made for the compound implies (if the organization’s research focus is the compound then (if the compound is a drug candidate then the compound is a therapeutic agent)), then a publication is released for the compound)) implies the collaboration of the organization is not suspended, then the organization’s funding is revoked.",
      "Rule39: Should it not be the case that the compound not being a game changer implies a competing drug exists for the disease, then there is market competition for the compound.",
      "Rule40: In case the compound is not a game changer, an adverse event is reported for the compound.",
      "Rule41: Whenever the compound is not a game changer, the compound is not approved."
    ],
    "facts": [
      "Fact1: A breakthrough discovery was made for the compound.",
      "Fact2: The compound is in a clinical trial.",
      "Fact3: The organization is a research leader.",
      "Fact4: The organization is part of a research consortium.",
      "Fact5: It is not the case that the clinical trial of the compound is halted.",
      "Fact6: It is not the case that public concern arises about the compound.",
      "Fact7: A publication was not released for the compound.",
      "Fact8: A competing drug does not exist for the disease.",
      "Fact9: The organization’s funding is not revoked.",
      "Fact10: The compound does not have a manufacturing problem.",
      "Fact11: The compound does not achieve market launch."
    ]
  },
  "question": "The compound is a game changer."
}